Australia: Safety advisory: Lida (Plus) capsules contain the undeclared substances sibutramine and phenolphthalein (English Only)
 
The Therapeutic Goods Administration (TGA) has tested a product labelled Lida (Plus) capsules and found that the capsules contain the undeclared substances sibutramine and phenolphthalein. Consumers are advised that sibutramine and phenolphthalein are prescription-only medicines. Sibutramine (which was the active ingredient in Reductil) was withdrawn in October 2010 after a study showed an increased risk of major cardiac events. Phenolphthalein was previously marketed as an oral laxative, withdrawn from sale from many markets in the late 1990's due to concerns over its carcinogenicity with long term use. 

TGA investigations have shown that a number of people in Australia may have bought the product online. Consumers are advised to stop taking the product and take any remaining capsules to their local pharmacy for safe disposal. If they have any concerns arising from their use of this product, consult their health care practitioner. 

Please refer to the following website in TGA for details: http://www.tga.gov.au/alert/lida-plus-capsules 

In Hong Kong, the above product is not a registered pharmaceutical product. 

Ends/Wednesday, Mar 28, 2018 
Issued at HKT 15:00 

 轉載自衛生署藥物辦公室網頁http://www.drugoffice.gov.hk/